Skip to main content
OpenTrials
Completed

NCT Number: NCT02091219

Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function

The purpose of this study is to compare the effects of two different forms of vitamin D supplements (vitamin D3 and 25-hyrdroxyvitamin D3 [25(OH)D3]) on vitamin D levels in the blood, and on markers of skeletal and immune health. This study is designed as a pilot study. A multi-ethnic cohort of 48 patients will be included (12 Caucasian, 12 African American, 12 Hispanic/Latino, 12 Asian/Asian American). Potential study candidates will undergo a screening visit during which a medical history will be taken, a physical exam performed, a dietary questionnaire administered, and blood collected. The purpose of the screening visit is to identify vitamin D-deficient (25-hydroxyvitamin D <20 ng/ml) individuals who are candidates for vitamin D supplementation. Eligible patients will then be randomly assigned to receive either vitamin D3 (2400 IU/day) or 25(OH)D3 (20 mcg/day) for 16 weeks. After initiating supplementation, study patients will return for follow-up visits at weeks 4, 8, and 16. At each visit, blood will be collected to assess vitamin D levels in the blood, as well as markers of skeletal and immune function. Participation in this study will therefore involve a total of 5 visits (1 screening visit, 1 randomization visit during which participants will receive their study supplements, 3 follow-up visits). After all data is collected, changes in vitamin D levels in the blood following supplementation with either vitamin D3 versus 25(OH)D3 will be determined, and correlated to markers of calcium balance and immune function. Knowledge gained from this study may have a significant impact on how vitamin D status is defined, and how vitamin D repletion is administered.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

UCLA Clinical and Translational Research Center (CTRC), Los Angeles, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18
  • 25D < 20 mg/ml

Exclusion criteria

  • Age < 18
  • 25D > 20 ng/ml at time of screening
  • Clear signs of infection at time of screening (coughing, sneezing, wheezing, frequency, dysuria)
  • History of conditions that would influence intestinal absorption of vitamin D3 or 25OHD3 supplements
  • History of nephrolithiasis, primary hyperparathyroidism, or other metabolic bone disease
  • History of chronic kidney disease (defined as CrCl < 30 ml/min)
  • History of rheumatologic or autoimmune conditions
  • History of sarcoidosis
  • History of active or latent tuberculosis
  • History of HIV
  • History of hyperthyroidism
  • History of chronic glucocorticoid use defined as the equivalent of 5 mg of prednisone per day for more than 2 months within the last 6 months
  • History of use of medications known to affect calcium/vitamin D metabolism, bone metabolism, and immune response
  • Hypercalcemia
  • Hypercalcinuria

Treatment and study plan

Vitamin D

Drug

2400 IU/day by mouth for 16 weeks

Other names: Cholecalciferol

25(OH)D3

Drug

20 micrograms/day by mouth for 16 weeks

Other names: Calcifediol, HyD

Primary outcomes

  1. Change in total serum 25D

    Time frame: 16 weeks

Secondary outcomes

  1. Change in serum free 25D

    Time frame: 16 weeks

  2. Change in serum total 1,25D

    Time frame: 16 weeks

  3. Change in total free 1,25D

    Time frame: 16 weeks

  4. Change in serum calcium

    Time frame: 16 weeks

  5. Change in urinary calcium

    Time frame: 16 weeks

  6. Change in serum iPTH

    Time frame: 16 weeks

  7. Change in serum bone turnover markers

    Time frame: 16 weeks

  8. Change in markers of immune function

    Time frame: 16 weeks

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Registry information

Official study title

The Effects of Vitamin D3 Versus 25OHD3 (HyD) on Serum Vitamin D Metabolites and Markers of Mineral Metabolism and Immune Function

Important dates

Study start
2014
Primary completion
2019
Study completion
2019
First posted
Mar 19, 2014
Registry last updated
Apr 28, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.